Navigation Links
Luoxin Announces 2008 Third Quarterly Results; Profit Attributable to Shareholders Surged 62.9% to Approximately RMB 138,141,000
Date:10/28/2008

Obtained Shareholders' Approval on the Proposed Transfer of Listing of its

H Shares from GEM to the Main Board

HONG KONG, Oct. 28 /Xinhua-PRNewswire/ -- Shandong Luoxin Pharmacy Stock Co., Ltd. (HKEx: 8058), announced its third quarterly results for the nine months ended 30 September 2008, recording a strong growth in turnover and profit attributable to shareholders.

The Company's turnover rose 36.9% year-on-year to approximately RMB480,155,000, while gross profit increased by 45.6% to approximately RMB237,382,000. Profit attributable to shareholders surged by 62.9% to approximately RMB138,141,000. Basic earnings per share were RMB22.66 cents, representing an increase of 62.9% over the corresponding period in 2007.

As at 30 September 2008, the Company obtained a strong balance sheet with sufficient working capital and no debt.

During the period under review, the Company's Technology Center was certified as Province-Class Technology Center and joined forces with Shenyang Pharmacy University by establishing the Shenyang Pharmacy University and Luoxin Pharma post-doctorate workstation, Shenyang Pharmacy University and Luoxin Pharma education and training station, Shenyang Pharmacy University and Luoxin Pharma intern station. This cooperation has not only enhanced the technological advancement of Luoxin Pharma, but also served as a platform for technology interchange and nurture of talents, laying a solid foundation for the Company's future development.

In order to capture the huge market opportunity in the market, the Company's phase three capacity expansion plan has been completed and commenced operation. The production capacity of aseptic raw material and raw material for system-specific medicines has thus increased by 200 each.

Mr. Liu Baoqi, Chairman of Luoxin Pharma said, "The Company has recently obtained the shareholders' approval for the proposed transfer of listing of its H shares from GEM to the Main Board at the EGM and the respective Class Meetings on 24 October 2008. We believe that the listing on the Main Board not only helps further enhancing the profile of the Group and increases the trading liquidity of the Shares of the Company and recognition, but will also be of great benefit to future growth and business development of Luoxin Pharma in the long run."

For further information, please contact:

Porda International (Finance) PR Group

Ms. Kelly Fung

Tel: +852-3150-6763

Ms. Kate Lam

Tel: +852-3150-6738


'/>"/>
SOURCE Shandong Luoxin Pharmacy Stock Co., Ltd.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. UCB Announces 2008 UCB Family RA Scholarship Program Recipients
2. QLT announces third quarter results for 2008
3. QLT announces encouraging Phase II data from core study of Punctal Plug Drug Delivery System
4. Response Biomedical Announces Insider Participation in Current Financing
5. American National Announces Third Quarter 2008 Results
6. Digestive Care, Inc. Announces the Complete Submission of the NDA for PANCRECARB(R) (pancrelipase)
7. U.S. Preventive Medicine(R) Announces Major Development for The Prevention Plan(TM)
8. Haemonetics Announces Promotion of Brian Concannon to CEO Effective April 2009
9. HLTH Corporation Announces Commencement of Its Tender Offer
10. ReachMD XM 157 Announces Medical Information Feature on Treatment Options for Management of Hyponatremia
11. Memory Pharmaceuticals Announces Issuance of Key U.S. Patent for R3487/MEM 3454 and R4996/MEM 63908
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/16/2017)... Linda, Ca (PRWEB) , ... August 16, 2017 , ... ... innovators, engineers, and scientists from around the world, is excited to announce Andrew Ly ... him in his academic pursuits, covering textbook costs. , Ly, who is in ...
(Date:8/16/2017)... ... 16, 2017 , ... With a new PD diagnosis every nine minutes, research ... The grants are awarded through a competitive application process and reviewed by APDA’s Scientific ... and expertise in all areas relevant to PD research. The SAB meets annually ...
(Date:8/16/2017)... ... August 16, 2017 , ... Melbourne’s reign as the world’s most liveable city ... (EIU) annual Liveability Index. , The Index surveys 140 of the world’s cities and ... Melbourne has consistently come in the top three of the index. So what is ...
(Date:8/16/2017)... Fla. (PRWEB) , ... August 16, 2017 , ... ... and management company based in Vero Beach, announced today that two of their ... an organization that represents professionally managed senior living communities in Florida. The awards ...
(Date:8/16/2017)... City, Utah (PRWEB) , ... August 16, 2017 , ... ... on the Inc 5000 list for the fourth consecutive year. With 197% ... 5000 2017 list of the nation’s fastest growing companies. , Previous honors ...
Breaking Medicine News(10 mins):
(Date:8/15/2017)... Diplomat Pharmacy, Inc. (NYSE: DPLO), is now ... residents. Naloxone is available without a ... pharmacy, G-3320 Beecher Road. ... Administration, is intended to block or reverse the effects ... of consciousness. The medication is often carried by first ...
(Date:8/14/2017)... HACKENSACK, N.J. and PETACH TIKVAH, ... Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult ... for the second quarter ending June 30, 2017. ... advanced stages of preparing for our pivotal Phase 3 ... Chaim Lebovits , President and Chief Executive Officer ...
(Date:8/8/2017)... Second-quarter 2017 revenues of $876 ... from continuing operations Second-quarter ... $110 million Second-quarter 2017 ... Second-quarter 2017 adjusted diluted ... percent to $0.93 Second-quarter ...
Breaking Medicine Technology: